Rheumatoid arthritis (RA) is a chronic autoimmune disorder manifested by inflammation of the joints, resulting in pain, swelling and joint damage. Non-steroidal anti-inflammatory drugs (NSAIDs) normally manage RA symptoms by decreasing inflammation and receiving pain. Whatever it may be, their long term use is often restricted because of the potential side effects on the gastro intestinal system and cardio vascular risks. Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate are frequently prescribed first _ line treatments, targeting immune system dysfunction. Janus Kinase (JAKs) plays a major role in immune response and hematopoiesis. These enzymes transduce signals particularly from cytokines and growth factors, enhancing communication between cells of the immune system. Treatment of RA includes dermatological conditions, hematological disorders, inflammatory bowel disease (IBD) and Rheumatoid arthritis. Finally it is concluded that from traditional NSAIDs to cutting _ edge biologics and JAK inhibitors, the field continues to advance, facilitating hope for improved outcomes and a better quality of life for individuals living with Rheumatoid arthritis.